Hualan Biological Engineering Inc
Hualan Biological Engineering Inc., together with its subsidiaries, engages in the research, development, production, and sale of biological products in China and internationally. The company offers blood products, including human serum albumin, human prothrombin complex concentrate, human coagulation factor VIII, human fibrinogen, and freeze-dried human fibrin glue for surgical use, as well as intravenous, human, rabies, hepatitis B, and tetanus immunoglobulin for various therapeutic applications. It also provides vaccine products, such as influenza virus split, H1N1 influenza A virus split, quadrivalent influenza virus split, group A and C meningococcal polysaccharide, group ACYW135 meningococcal polysaccharide, recombinant hepatitis B vaccine, freeze-dried human rabies, and adsorbed tetanus vaccines. In addition, the company develops monoclonal antibody drugs and biosimilars comprising rituximab injection which is in Phase III clinical trials for the treatment of CD20-positive diffuse large B-cell/follicular non-Hodgkin lymphoma and chronic lymphocytic leukemia; adalimumab injection which is in Phase III clinical trials for the treatment of various autoimmune diseases; denosumab injection which is in Phase III clinical trials for the treatment of patients with bone metastases; injectable trastuzumab which is in Phase III clinical trials for the treatment of HER2-positive metastatic/early-stage breast cancer and metastatic gastric cancer; and recombinant Exendin-4-FC fusion protein injection which is in Phase I/II clinical trials for the treatment of type 2 diabetes. Further, it is involved in the research and development of poultry farming; plasma collection; engineering technology research and experimental development; and inspection and testing services. The company was founded in 1992 and is headquartered in Xinxiang, China.
If you'd bought from year…
Same habit, different start year. Each row shows what a constant habit's worth of 002007-SZ would be worth today, had you started buying at that point in the asset's history.
| Started | $6/day$6/day coffee | $42/wk$42/week coffee |
|---|---|---|
| Year 1 (2004) — listing | $129,486 4.0× | $185,838 4.0× |
| Year 6 (2009) | $29,216 1.2× | $43,022 1.2× |
| Year 11 (2014) | $15,626 0.9× | $23,068 0.9× |
| Year 16 (2019) | $7,124 0.7× | $10,517 0.7× |
| Year 21 (2024) | $3,005 0.9× | $4,489 0.9× |
Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.
Popular scenarios with 002007
For illustration only — not investment advice. Past performance is not indicative of future results.